PI3K/p110β-specific inhibitors in castration-resistant prostate cancer / 中华男科学杂志
National Journal of Andrology
;
(12): 195-199, 2017.
Artículo
en Chino
| WPRIM
| ID: wpr-812787
ABSTRACT
Advanced prostate cancer, especially at the castration-resistant stage, remains incurable clinically and, therefore, urgently requires new therapeutics for the patients. PI3K is a family of critical cell signal transduction molecules and their over-activation is an important factor in cancer development and progression. It has been demonstrated that class IA PI3K p110 is drastically overexpressed in prostate cancer and involved in androgen receptor-mediated gene expression and castration-resistant progression and regarded as a potential therapeutic target for prostate cancer. Several p110-specific inhibitors have been reported recently and two of them, GSK2636771 and AZD8186, are being tested in clinical trials.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Morfolinas
/
Cromonas
/
Fosfatidilinositol 3-Quinasas
/
Usos Terapéuticos
/
Inhibidores de Proteínas Quinasas
/
Quimioterapia
/
Neoplasias de la Próstata Resistentes a la Castración
/
Inhibidores de las Quinasa Fosfoinosítidos-3
/
Imidazoles
/
Compuestos de Anilina
Límite:
Humanos
/
Masculino
Idioma:
Chino
Revista:
National Journal of Andrology
Año:
2017
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS